This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources.Find sources: "Methyl-DMA" – news · newspapers · books · scholar · JSTOR (July 2019)
Methyl-DMA
Names
Preferred IUPAC name
1-(2,5-Dimethoxyphenyl)-N-methylpropan-2-amine
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C12H19NO2/c1-9(13-2)7-10-8-11(14-3)5-6-12(10)15-4/h5-6,8-9,13H,7H2,1-4H3 checkY
    Key: RSDBPMOXIPCTPN-UHFFFAOYSA-N checkY
  • InChI=1/C12H19NO2/c1-9(13-2)7-10-8-11(14-3)5-6-12(10)15-4/h5-6,8-9,13H,7H2,1-4H3
    Key: RSDBPMOXIPCTPN-UHFFFAOYAQ
  • O(c1ccc(OC)cc1CC(NC)C)C
Properties
C12H19NO2
Molar mass 209.289 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

Methyl-DMA (2,5-dimethoxy-N-methylamphetamine) is a lesser-known psychedelic drug and substituted methamphetamine. It was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 250 mg, and the duration unknown.[1] Methyl-DMA produces slight paresthesia. Very little data exists about the pharmacological properties, metabolism, and toxicity of Methyl-DMA.

See also

References

  1. ^ Methyl-DMA entry in PiHKAL


Categories